Mineralys therapeutics inc MLYS.US 總覽分析

美股醫療保健
(MLYS 無簡報檔)

MLYS 投資分析

看多重點：

  • 價值≥4
  • 股利≥2

分析結論

公司發布財報數據季度不足，尚無法提供評分

MLYS 近期報酬表現

3.07%

Mineralys therapeutics inc

3.56%

同產業平均

1.47%

S&P500

與 MLYS 同產業的標的表現

  • XENE Xenon pharmaceuticals inc
    價值 2 分趨勢 4 分波段 4 分籌碼 3 分股利 1 分
    查看更多

MLYS 公司資訊

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and in subjects with hypertension and OSA.

MLYS 股價